Enhanced to Participate in the CG WELL Summit Hosted by Canaccord Genuity

Enhanced Group’s CEO will speak on an aging and therapeutics panel at the CG WELL Summit and hold investor meetings during the event.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NEW YORK--(BUSINESS WIRE)-- Enhanced Group, Inc. (NYSE: ENHA) (“Enhanced” or the “Company”), the personalized performance products and elite sports competition company, today announced that management will participate in the CG WELL Summit taking place September 28-30 in New York City.

Maximillian Martin, Chief Executive Officer of Enhanced, will participate in a panel titled “Aging on Trial: Peptides, Hormones, and the Line Between Breakthrough and Hype” at 11:15 AM ET on September 29 and will be available for meetings with investors during the conference. A replay of the panel webcast will be available on the Enhanced investor relations website at investors.enhanced.com following the conclusion of the conference.

For more information, or to schedule a meeting with management, please reach out to your Canaccord Genuity representative.

About Enhanced Group, Inc.

Enhanced (NYSE: ENHA) is an elite sports competition and performance products company committed to giving athletes and consumers access to products that optimize health, performance, and recovery. Its Live Enhanced platform provides consumers with clinician-guided protocols, supplements, and personalized health and longevity offerings. For more information, visit www.enhanced.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260914546191/en/

Investors
enhanced@icrinc.com

Media
media@enhanced.com

Source: Enhanced Group, Inc.

Key Terms

peptides medical

Peptides are short chains of amino acids—the building blocks of proteins—that act like tiny messengers or tools in the body to trigger or block biological processes. Investors care because peptides are used as medicines, diagnostics, and research tools with potential for targeted treatments, often faster and cheaper to develop than large proteins; their commercial value depends on clinical results, manufacturing scalability, patent protection and regulatory approval.